Patients with idiopathic pulmonary fibrosis (IPF) may have a new treatment option, according to researchers in Japan.
The Coalition for Pulmonary Fibrosis (CPF) applauds the joint statement issued by the American Thoracic Society for the first evidence-based clinical guidelines for the treatment of idiopathic pulmonary fibrosis (IPF). The guidelines represent progress in understanding of the disease and a milestone for patients. The devastating and deadly disease also called simply "Pulmonary Fibrosis" or "PF" has no FDA approved treatment and no cure.
An article published in Experimental Biology and Medicine (Volume 244, Issue 9, June 2019) ( identifies a new target for the treatment of idiopathic pulmonary fibrosis.
They found that the anti-cancer drug imatinib mesylate — commercially known as Gleevec and produced by Novartis Pharmaceuticals — can target a gene critical to controlling the disease process. Previously, there had been no treatment and patients usually did not survive beyond three years of diagnosis. Now the treatment is undergoing clinical trials at Mayo Clinic.
Investigators at the University of Alabama at Birmingham (UAB) have unlocked another piece of the puzzle surrounding idiopathic pulmonary fibrosis, an often fatal lung disease with no cure and no effective treatments.
Updated guidelines on the treatment of idiopathic pulmonary fibrosis (IPF) have been released by an international group of leading respiratory societies, The new guidelines, issued by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association, were published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.
A Yale-led collaborative study boosts scientific understanding of how the lung disease idiopathic pulmonary fibrosis (IPF) progresses, providing a roadmap for researchers to discover new treatment targets for the disease.
Compugen Ltd. and the Pulmonary Fibrosis Foundation announced today that the Pulmonary Fibrosis Foundation will provide a grant to scientists at the University of Pittsburgh Dorothy P. and Richard P.